Find Clinical Trial

Home » Find Clinical Trials » A Multicentre, Phase II Randomized Study, Open-label, With 2-arm Parallel Group, Comparing the Pharmacokinetics of the Liquid and the Lyophilized Formulations of Pegaspargase (S95014) in Treatment of Paediatric Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

A Multicentre, Phase II Randomized Study, Open-label, With 2-arm Parallel Group, Comparing the Pharmacokinetics of the Liquid and the Lyophilized Formulations of Pegaspargase (S95014) in Treatment of Paediatric Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

← Back

Study Phase	Phase 2

Therapeutic Area	Cancers

Indication	Acute Lymphoblastic Leukemia

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	PEGASPARGASE, S095014

Active Substance Code	S095014

Protocol Code	CL2-95014-002

EudraCT Code	2020-004894-29

NCT Code	NCT04954326

Documents and links

Lay summary

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.